Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Core Insights - Trevi Therapeutics, Inc. is developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC) [2][3] Company Overview - Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on Haduvio™, which is the first investigational therapy to demonstrate a statistically significant reduction in cough frequency in clinical trials for both IPF chronic cough and RCC [2] - Haduvio acts on the cough reflex arc as a kappa agonist and mu antagonist (KAMA), targeting opioid receptors involved in chronic cough control [2] Industry Context - Chronic cough in patients with IPF and non-IPF ILD represents a significant unmet medical need, with approximately 150,000 U.S. patients with IPF, two-thirds of whom experience uncontrolled chronic cough [3] - There are around 228,000 U.S. patients with non-IPF ILD, with 50-60% suffering from uncontrolled chronic cough, leading to severe impacts on morbidity and mortality [3] - RCC affects approximately 2-3 million U.S. patients and is characterized by a persistent cough lasting over 8 weeks despite treatment for underlying conditions, with significant physical, psychological, and social impacts [4]